Online inquiry

IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15592MR)

This product GTTS-WQ15592MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC29A2 gene. The antibody can be applied in Glycogen storage disease type II (GSD-II) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15592MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3305MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ4544MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ13964MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ12254MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ13227MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ2029MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ7350MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ7629MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.